EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer Meeting Abstract
| Authors: | Hoimes, C. J.; Petrylak, D. P.; Flaig, T. W.; Carret, A. S.; Melhem-Bertrandt, A.; Rosenberg, J. E. |
| Abstract Title: | EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer |
| Meeting Title: | 2018 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2018 Feb 8-10 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-20 |
| Language: | English |
| ACCESSION: | WOS:000436179500525 |
| DOI: | 10.1200/JCO.2018.36.6_suppl.TPS532 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS532 -- Source: Wos |
